Exploiting such so-called synthetic lethality (SL), where PARP inhibitors drive the accumulation of cytotoxic DNA intermediates that are normally resolved via HRR, has motivated improved drug design/application and has led to better outcomes for many of these cancer-affected individuals [8]. Here, PARP1 is linked to cancer.